Neurogene Announces Upcoming Presentations Highlighting Key Differentiators of NGN-401 for Rett Syndrome at the ESGCT 33rd Annual Congress
Neurogene will present new data on its NGN-401 gene therapy for Rett syndrome at the ESGCT 33rd Annual Congress, October 27-30, 2026, in Hamburg. Presentations cover expression kinetics of single-stranded AAV delivery, early time-to-response from the Phase 1/2 trial, and in vivo evaluation of the company's EXACT miRNA-based transgene regulation technology.
Key figures
- Drug Name
- NGN-401
- Phase Of Trial
- Phase 1/2 (Embolden registrational trial)
- Dose
- 1E15 vg
- Congress
- ESGCT 33rd Annual Congress, Oct 27-30, 2026, Hamburg
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.